| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 19th July 2019 | Dmitry Genkin | 93,390 | Grant/award etc. | $0.00 | |
| 14th March 2018 | Dmitry Genkin | 29,452 | Other acquisition or disposition | $0.00 |
Xenetic Biosciences
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Xenetic Biosciences, Inc. is a biopharmaceutical company, which focuses on progressing XCART, a personalized CAR T platform technology. The company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's tumor cells.
Ticker: XBIO
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1534525
Employees: 4
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
Q&A: Google, US government prepare for battle over market power
21st October 2020
Amazon extends work from home option till June
21st October 2020
Snap beats analyst estimates for user growth, revenue
20th October 2020
Shale producer Pioneer Natural to buy rival Parsley
20th October 2020